RetinalGenix Technologies Inc. (RTGN)
Oxford Ledge is still expanding full research coverage of RTGN. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
RetinalGenix develops ophthalmic screening and treatment technologies and therapies, with no approved products or revenue to date.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-20
- 10-K Annual financial report with audited statements 2026-04-15
- 8-K Departure/election of directors or officers 2026-03-26
- 10-Q Quarterly financial report (unaudited) 2025-11-14
- 10-Q/A Amended quarterly report 2025-08-20
Source: SEC EDGAR.
- Open RTGN in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.